ライフサイエンスコーパス: CDAI

1 CDAI and goal interval scores (GIS) were assessed at wee

2 CDAI was used to assess response.

3 CDAI, CRP, fecal calprotectin and VCE Lewis inflammatory

4 maintenance trial was remission at week 44 (CDAI score <150).

5 s entered a sustained remission defined by a CDAI < or =150.

6 east 100 points) and remission (defined by a CDAI score of 150 or less) were secondary end points.

7 cent, P=0.01) and of remission, defined by a CDAI score of 150 points or less on day 57 (40 percent v

8 Ten vs 2 patients had a CDAI less than 150 (remission) at the final evaluation,

9 agonist failure given vedolizumab also had a CDAI-100 response (>/=100-point decrease in CDAI score f

10 d 25.7% of the patients, respectively, had a CDAI-100 response (>/=100-point decrease in the CDAI sco

11 iving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response t

12 ity Index [CDAI] score of >/=100 points or a CDAI score <150).

13 come in both trials was disease remission (a CDAI score of less than 150).

14 All patients went into remission with a CDAI less than 150.

15 e (P<.0001 for both), the 33 patients with a CDAI of at least 150 (P<.032 and P<.0074, respectively),

16 sponding to high levels of disease activity (CDAI/SDAI) or moderate levels of disease activity (DAS/D

17 re set measure thresholds, SDAI <or=3.3, and CDAI <or=2.8.

18 endoscopy (VCE), CRP, fecal calprotectin and CDAI.

19 001) of CD recurrence, but the CRP level and CDAI score did not.

20 moderate positive correlation between PE and CDAI (r=0.65, p<0.001).

21 Symptoms and CDAI improved before hospital discharge, whereas radiogr

22 al management group after random assignment: CDAI decrease of <100 points compared with baseline or C

23 l management group before random assignment: CDAI decrease of <70 points compared with baseline or CD

24 Time-averaged CDAI also showed a better fit.

25 41-0.997 per year; p=0.048) and low baseline CDAI (0.82, 0.74-0.98 per 10 units; p=0.031).

26 The mean DAS, DAS28, CDAI score, and SDAI score were 3.7, 4.7, 30.8, and 36.4

27 abilities were seen between the DAS, DAS28, CDAI, and SDAI for the ACR pediatric criteria for improv

28 responded to low disease activity (DAS/DAS28/CDAI) or moderate disease activity (SDAI).

29 (ii) Both treatments decreased CDAI, increased IBDQ scores, and normalized the ReHo val

30 ubgroups of patients with respect to gender, CDAI scores, disease location, clinical behavior (obstru

31 The study's primary endpoint was change in CDAI at week 2.

32 Response to infliximab as median change in CDAI was placebo (least response) < perinuclear ANCA (pA

33 Overall, 12 patients had a decrease in CDAI of more than 100 points, and eight achieved clinica

34 CDAI-100 response (>/=100-point decrease in CDAI score from baseline) at week 6 than those given pla

35 Decreases in CDAI score by 70 or more and 100 or more points (seconda

36 luminal disease was defined as reduction in CDAI score of >150 points and for fistula patients was 2

37 ith a statistically significant reduction in CDAI.

38 defined by a Crohn's Disease Activity Index (CDAI) < 150, underwent a gastric emptying test by breath

39 cal remission (Crohn Disease Activity Index (CDAI) <150 [range, 0-600]), no use of corticosteroids or

40 levels, and Crohn's Disease Activity Index (CDAI) and Inflammatory Bowel Disease Questionnaire (IBDQ

41 oints in the Crohn's Disease Activity Index (CDAI) at the end of treatment (day 57).

42 Crohn's Disease Activity Index (CDAI) data from the North American patients in the clini

43 ) defined as a Crohn Disease Activity Index (CDAI) greater than 250, and/or Crohn Severity Index grea

44 , defined by a Crohn Disease Activity Index (CDAI) higher than 250 despite anti-tumor necrosis factor

45 reduction in Crohn's Disease Activity Index (CDAI) of 100 points, was observed in 40% of patients at

46 h ulcers), a Crohn's Disease Activity Index (CDAI) of 150-450 depending on dose of prednisone at base

47 defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with mucosal ulcers in the ileum or co

48 f age with a Crohn's Disease Activity Index (CDAI) of 250-400 despite conventional therapies includin

49 e also used clinical disease activity index (CDAI) or data in the BeSt study (European population).

50 t 220 on the Crohn's disease activity index (CDAI) received a 5 mg/kg intravenous infusion of inflixi

51 <or=11 and Clinical Disease Activity Index (CDAI) score <or=10.

52 ease in mean Crohn's disease activity index (CDAI) score during treatment (p<0.0001).

53 rease in the Crohn's Disease Activity Index (CDAI) score of at least 70 points, at week 10.

54 defined as a Crohn's Disease Activity Index (CDAI) score of less than 150, with maintenance of remiss

55 atients with Crohn's Disease Activity Index (CDAI) scores of > or = 250 and < or = 500 despite > or =

56 n (CRP), and Crohn's disease activity index (CDAI) scores were measured before surgery and then at 6,

57 estinal, the Crohn's Disease Activity Index (CDAI) was used to assess response.

58 activity (CICDA), (b) the CD activity index (CDAI), and (c) the simplified endoscopic score for CD (S

59 inflammation and clinical CD activity index (CDAI).

60 I), and the Clinical Disease Activity Index (CDAI).

61 n's disease (Crohn's Disease Activity Index [CDAI] > 200 and/or draining perianal disease) initiated

62 n's disease (Crohn's Disease Activity Index [CDAI] > or =151 and < or =450) received a 3-mg/kg infusi

63 after HSCT (Crohn's Disease Activity Index [CDAI] <150).

64 score on the Crohn's Disease Activity Index [CDAI] of </=150, with scores ranging from 0 to approxima

65 core for the Crohn's Disease Activity Index [CDAI] of at least 100 points) and remission (defined by

66 eline in the Crohn's Disease Activity Index [CDAI] score of >/=100 points or a CDAI score <150).

67 ly to severely active CD (CD activity index [CDAI] score, 220-400 points) were assigned randomly to g

68 n >/=250 mug/g, C-reactive protein >/=5mg/L, CDAI >/=150, or prednisone use in the previous week; cli

69 After 8 weeks of treatment, mean CDAI had fallen by 190 points.

70 The initial median CDAI was 291 (range, 250-358).

71 The median CDAI score at entry was 371 (95-468).

72 The median CDAI score was 175 (30-468; P < 0.001 vs. baseline).

73 corresponded to low (DAS/DAS28) or moderate (CDAI/SDAI) disease activity.

74 In this group, remission (based on CDAI </=150) was observed in 3 of 8 patients (38%) at we

75 ase of <100 points compared with baseline or CDAI >/=200, or prednisone use in the previous week).

76 ease of <70 points compared with baseline or CDAI >200; clinical management group after random assign

77 ence with greater accuracy than CRP level or CDAI score.

78 ibustion group, were correlated with reduced CDAI.

79 The primary outcome was clinical remission (CDAI <150) at week 12 (intention-to-treat population).

80 roportion of patients in clinical remission (CDAI, </=150 points) at week 6.

81 Patients have remained in remission (CDAI < 100) for 1 year since HSCT.

82 The percentage of patients in remission (CDAI < 150), steroid-free, or medication-free at any pos

83 o responded at week 2 and were in remission (CDAI <150) at week 30 and the time to loss of response u

84 The CDAI score decreased from 270 points (preinfusion) to 13

85 At week 2, the CDAI decreased significantly from baseline after infusio

86 from baseline of at least 100 points in the CDAI score on day 57 (48 percent vs. 26 percent, P=0.01)

87 d by a decrease of at least 70 points in the CDAI score on day 57 between the sargramostim and placeb

88 I-100 response (>/=100-point decrease in the CDAI score) (P=0.23).

89 as a reduction of 100 points or more in the CDAI score) at day 28.

90 Clinical remission was defined as a total CDAI < 150 (luminal patients) or >/=2+ for all parameter

91 l regions were significantly correlated with CDAI score decreases.

92 isease detected in LDCTE and correlates with CDAI.